Cost per response analysis of repository corticotropin injection versus other alternative treatments for acute exacerbations of multiple sclerosis

Background Relapses are common in patients with multiple sclerosis (MS) even after the use of disease-modifying therapies. Repository corticotropin injection (RCI), plasmapheresis (PMP), and intravenous immunoglobulin (IVIg) may be utilized as alternative therapies in the management of MS relapse. There is a lack of health economic studies on these alternative therapies for the acute exacerbations of MS. The objective of this study was to estimate the cost per response of RCI compared with PMP or IVIg from the United States (US) commercial payer perspective. Methods Costs and response rates were sourced from published peer-reviewed observational studies. The cost of care included MS-related inpatient, outpatient, and medication costs. Treatment response was defined as no evidence of additional relapse treatment or procedure claims within 30 days after treatment. The cost per response for each treatment was calculated by dividing the total annual cost of care by the proportion of patients with resolved relapse for each treatment. The incremental cost per response ratio was calculated by dividing the difference in costs and the proportion of responses for RCI versus PMP or IVIg. One-way sensitivity analysis (OWSA) was conducted for both costs and response rates. All included costs were inflated to the 2019 US dollars. Results With a lower total annual cost of care and a higher response rate, RCI had a lower cost per response (US$141,970) compared with PMP or IVIg (US$253,331). RCI had a lower cost per response even when more stringent estimates for RCI were applied in the OWSA. The annual cost of care had a greater influence on the cost per response in the OWSA. Conclusions Based on the estimates from the real-world evidence, our economic evaluation suggests that RCI may have real-world clinical and economic benefits for patients with MS relapse who fail on corticosteroid therapy.

[1]  T. Nazareth,et al.  Treatment Effectiveness for Resolution of Multiple Sclerosis Relapse in a US Health Plan Population , 2019, Neurology and Therapy.

[2]  T. Nazareth,et al.  Efficacy, safety, and quality-of-life of treatments for acute relapses of multiple sclerosis: results from a literature review of randomized controlled trials , 2019, Degenerative neurological and neuromuscular disease.

[3]  Robert C Reiner,et al.  Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2019, The Lancet Neurology.

[4]  T. Nazareth,et al.  Relapse prevalence, symptoms, and health care engagement: patient insights from the Multiple Sclerosis in America 2017 survey. , 2018, Multiple sclerosis and related disorders.

[5]  R. Hansen,et al.  Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel® , 2016, Advances in Therapy.

[6]  M. Sormani,et al.  Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010. , 2012, International journal of MS care.

[7]  J. Castelli-Haley,et al.  Burden of a Multiple Sclerosis Relapse , 2012, The Patient - Patient-Centered Outcomes Research.

[8]  I. Elovaara,et al.  Intravenous Immunoglobulins Are a Therapeutic Option in the Treatment of Multiple Sclerosis Relapse , 2011, Clinical neuropharmacology.

[9]  M. Lopez-Bresnahan,et al.  Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims , 2010, Journal of medical economics.

[10]  D. Goodin,et al.  Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures , 2009, Neurology.

[11]  J Lyle Bootman,et al.  Value in health care. , 2006, Managed care interface.

[12]  H. Hartung,et al.  Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders. , 2006, Archives of neurology.

[13]  P. Sørensen,et al.  IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS , 2004, Neurology.

[14]  B. Weinshenker,et al.  A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease , 1999, Annals of neurology.

[15]  R. Berkovich.  Treatment of Acute Relapses in Multiple Sclerosis , 2012, Neurotherapeutics.

[16]  A. Zbrozek,et al.  The economic burden of Medicare-eligible patients by multiple sclerosis type. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.